Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

It's Time for Bargain Shopping in the Biotech Aisle

Dynavax Technologies, Kala Pharmaceuticals and TherapeuticsMD are three names this biotech investor plans to add exposure to via covered calls.

Tuesday's Market Hiccup Spelled Opportunity to Buy 2 Stocks

Gold Resource Corp. should benefit as inflationary pressures rise and Travelzoo should improve as normal life returns.

Inflation Signs Are Everywhere

The central bank chooses to be myopic for the time being.

A Trifecta of Bad News Makes for a Rough Day for This Biotech Investor

Shares of Cara Therapeutics, Adverum Biotechnologies and Ardelyx Inc. all took big hits after each company announced unfavorable developments.

Checking In on the Late 1960s to See What Inflation Could Look Like Soon

There are similarities between conditions more than 50 years ago and the present state of affairs that should give investors cause for concern.

Investors Don't Seem to Be Pricing In Hurtful Impact of Radical Biden Policies

The administration's actions and plans aren't friendly to either investors or business operators.

You've Got Volatility 'Covered' With This Strategy

This simple option strategy, which I continue to use with small-cap biotechs, is one of the easiest and cheapest risk mitigation approaches an individual can take.

How to Navigate a Painful Biotech Sector

Biotech stocks as a group have struggled in recent weeks; here's a strategy for mitigating risk when investing in these names.

2 Health-Related Stocks See Bits of Insider Interest

Large purchases of Cortexyme Inc. and NantHealth Inc. shares have been made by insiders recently.

My Favorite Day of the Month: Options Expiration Day

I have become a huge devotee of this simple option strategy. Here are two recent examples from this week.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight